SynthesisPathology oncology research : POR2019
Long Noncoding RNA PVT1 as a Novel Predictor of Metastasis, Clinicopathological Characteristics and Prognosis in Human Cancers: a Meta-Analysis.
Synthesis in Pathology oncology research : POR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Long non-coding RNA as a potential diagnostic and prognostic biomarker in melanoma: A systematic review and meta-analysis.Journal of cellular and molecular medicine · 2024Pooled it
- Long non-coding RNA MIR31HG as a prognostic predictor for malignant cancers: A meta- and bioinformatics analysis.Journal of clinical laboratory analysis · 2022Pooled it
- AI-Guided Long Non-Coding RNA Target Discovery for Precision Medicine: Integrating GWAS, Multi-Omics, Experimental Validation, and RNA Therapeutics.Biomedicines · 2026Review
- Scrutinizing the potential role of non-coding RNAs as biomarkers in Egyptian females with early and metastatic breast cancer.BMC cancer · 2026Article
- Diagnostic and therapeutic role of non-coding RNAs regulating programmed cell death in melanoma.Frontiers in oncology · 2024Review
- Long non-coding RNA PVT1 promotes the proliferation, migration and EMT process of ovarian cancer cells by regulating CTGF.Oncology letters · 2023Article
- Long non-coding RNA PVT1 facilitates cell migration and invasion by regulating miR-148a-3p and ROCK1 in breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Long Noncoding RNAInternational journal of molecular sciences · 2020Article
- Hypoxia induces the activation of hepatic stellate cells through the PVT1-miR-152-ATG14 signaling pathway.Molecular and cellular biochemistry · 2020Article
- Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis.Cellular and molecular life sciences : CMLS · 2019Review
- Long noncoding RNA HOXD-AS1 in various cancers: a meta-analysis and TCGA data review.OncoTargets and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present meta-analysis aimed to systematically evaluates the metastasis, clinical stage, and prognostic value regarding the expression levels of PVT1 in various cancers. Relevant literatures were searched in PubMed、Cochrane Library、Wed of science、Embase databases、Chinese National Knowledge Infrastructure and Wanfang from inception up to 22 August 2017. After data were extracted, a meta-analysis was performed using Review Manager 5.3 and Stata 12.0 software. The meta-analysis showed that high expression of PVT1 could predict more lymph node metastasis (LNM) (Odds ratio, OR = 2.83, 95% confidence interval, CI: 1.76-4.54, P < 0.0001), distant metastasis (DM) (OR = 3.60, 95% CI: 1.08-12.03, P = 0.04), advanced clinical stage (OR = 4.37, 95% CI: 3.45-5.54, P < 0.00001) and poor overall survival (Hazard ratio, HR = 2.08, 95% CI: 1.82-2.37, P < 0.00001)in cancer. Subgroup analysis in different systems also showed the same results, including respiratory system、digestive system、urinary system and other systems, especially in respiratory system (LNM, OR = 4.57, 95% CI: 2.41-8.68, P < 0.00001; clinical stage, OR = 5.59, 95% CI: 3.59-8.71, P < 0.00001; OS, HR = 2.43, 95% CI: 1.98-2.99, P < 0.00001). These results suggest that PVT1 could serve as a novel biomarker for metastasis, clinical stage and poor prognosis in various tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.